Celyad Announces May 2019 Investor Conference Schedule
May 02, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress
April 17, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, April 17, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces April 2019 Investor Conference Schedule
April 01, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, April 01, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Reports Business Update and Full Year 2018 Financial and Operating Results
March 28, 2019 16:05 ET
|
Celyad SA
THINK Phase 1 trial (CYAD-01 with no preconditioning) showed a complete response in 40% of patients with AML/MDSTHINK CyFlu Phase 1 demonstrated CYAD-01 is well-tolerated, with no dose-limiting...
Celyad Appoints Filippo Petti as Chief Executive Officer
March 28, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 28, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Announce Full Year 2018 Financial Results and Host Conference Call
March 22, 2019 02:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates
March 18, 2019 16:01 ET
|
Celyad SA
shRNA platform complements Company’s all-in-one-vector approach in the design, discovery and development of next-generation CAR-T candidatesAllogeneic T-cells derived by shRNA targeting show...
Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City
March 11, 2019 02:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 11, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Appoints Anne Moore as Vice President Corporate Strategy
March 08, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 08, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces February and March 2019 Investor Conference Schedule
February 21, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...